NCT07591519招募中1 期
Evaluation of the Pharmacokinetics and Pharmacodynamics of IBI3035 and Awiqli? (Ecoporin Insulin Injection) in a Randomized, Open-label, Single-dose, Two-formulation, Crossover Design in Healthy Male Subjects in China: A Phase I Clinical Trial.
适应症
干预措施
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 入组人数
- 144
- 试验地点
- 1
研究概览
简要总结
This study is a Phase I clinical trial that uses positive glucose clamping technology to evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) bioequivalence of IBI3035 with insulin injection (Awiqli?) after a single administration in healthy male subjects
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Crossover
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 45 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •The following inclusion criteria must be met:
- •Healthy male adult subjects aged 18 to 45 years (including 18 and 45 years, based on the date of signing the informed consent form) of Chinese nationality;
- •Body Mass Index (BMI) between 19.0 and 24.0 kg/m2 (including both values) at screening, and weight ≥ 50 kg;
- •Normal glucose tolerance at screening [3.9 mmol/L < fasting blood glucose < 6.1 mmol/L, and 2-hour post-glucose load blood glucose < 7.8 mmol/L in the oral glucose tolerance test (OGTT)]; normal insulin secretion function or abnormality without clinical significance as determined by the investigator [confirmed by the insulin release test (IRT)];
- •Glycated hemoglobin ≤ 6.0% at screening;
- •Agree to take effective contraceptive measures during the study period and within 6 months after the last dose and have no plan to donate sperm;
- •Able to understand the procedures and methods of this study, willing to strictly follow the clinical trial protocol to complete the trial, and voluntarily sign the informed consent form.
排除标准
- •Subjects who meet any of the following exclusion criteria cannot be included in this study:
- •Known or suspected to be allergic to the investigational drug in this study;
- •Have taken any drugs that affect insulin hypoglycemic effects within 28 days before screening (such as corticosteroids, diuretics, epinephrine, salbutamol, glucagon, thyroid hormones, etc.);
- •Have a history of clinical significance as determined by the investigator at screening or before randomization, including diseases of the endocrine system, blood system, cardiovascular system, respiratory system, digestive system, urinary system, immune system, nervous system, or any other disease that can significantly alter the absorption, metabolism, or elimination of drugs;
- •Have a clear diagnosis of hyperglycemia or hypoglycemia within 3 months before screening;
- •Have an increased risk of thrombosis at screening, including personal or family history of deep vein thrombosis;
- •Have abnormal indicators with clinical significance at screening or before randomization: vital signs, physical examination, laboratory tests, chest X-ray, and 12-lead ECG as determined by the investigator;
- •Have had a severe infection, trauma, or surgery within 4 weeks before screening;
- •Have smoked more than 5 cigarettes per day within 3 months before screening, or have smoked within 48 hours before using the investigational drug or cannot stop using any tobacco products during the trial;
- •Have used any prescription drugs, Chinese herbal medicines, over-the-counter drugs, or health supplements (except for regular vitamin supplements) within 2 weeks before screening;
- •Have donated blood ≥ 400 ml or had any component blood donation within 3 months before screening, or have lost a total of ≥ 400 ml of blood for any reason, or have a history of blood transfusion or use of blood products;
- •Have consumed more than 14 units of alcohol per week within 3 months before screening: 1 unit ≈ 360 ml of beer, or 45 ml of spirits, or 150 ml of wine, and cannot abstain from alcohol within 48 hours before using the investigational drug;
- •Have consumed excessive amounts of tea, coffee, and/or caffeine-rich beverages (more than 8 cups, 1 cup ≈ 250 ml) daily within 3 months before screening;
- •Have positive results for human immunodeficiency virus (HIV) antibodies, hepatitis B surface antigen (HBsAg), hepatitis C virus (HCV) antibodies, or Treponema pallidum antibodies;
- •Have a history of drug abuse or drug use within 3 months before screening, or have positive results for alcohol tests or urine drug screening at screening.
- •Participants who have participated in other clinical trials and used investigational drugs or medical devices within the 3 months prior to screening;
- •16. Participants with a weight change greater than 5% within the 3 months prior to screening [(maximum weight within the 3 months prior to screening - minimum weight within the 3 months prior to screening) / minimum weight within the 3 months prior to screening × 100%, as self-reported by the participant];
- •Participants with any food allergies or special dietary requirements that prevent them from adhering to a uniform diet (such as intolerance to standard meal foods, lactose intolerance, etc.);
- •Participants who have experienced acute diseases during the screening period;
- •Participants with a history of fainting at the sight of needles or blood, who cannot tolerate venipuncture blood collection, or who have difficulty with blood collection;
- •Participants for whom the investigator deems there to be any circumstances that make them unsuitable for participation in the trial.
研究组 & 干预措施
Insulin icodec Injection
Active Comparator
The first cycle is Awiqli® 1 U/kg, and the second cycle is IBI3035 1 U/kg
干预措施: Insulin icodec Injection (Biological)
IBI3035
Experimental
The first cycle is IBI3035 1 U/kg, and the second cycle is Awiqli® 1 U/kg
干预措施: Insulin icodec Injection (Biological)
Insulin icodec Injection
Active Comparator
The first cycle is Awiqli® 1 U/kg, and the second cycle is IBI3035 1 U/kg
干预措施: IBI3035 (Biological)
IBI3035
Experimental
The first cycle is IBI3035 1 U/kg, and the second cycle is Awiqli® 1 U/kg
干预措施: IBI3035 (Biological)
研究者
研究点 (1)
Loading locations...
相似试验
招募中
1 期
A Study of SHR-2524 Plus Bevacizumab in the First-line Treatment of Advanced Hepatocellular CarcinomaNCT07478302Suzhou Suncadia Biopharmaceuticals Co., Ltd.36
招募中
1 期
A Study to Test How Different Doses of BI 3814916 Are Tolerated by Healthy PeopleNCT07486115Boehringer Ingelheim136
尚未招募
1 期
Safety and PK of MMV371 LAI in Healthy Adults and Adolescents in RwandaMalaria (Plasmodium Falciparum)Malaria FalciparumMalaria InfectionMalaria ProphylaxisMalaria PreventionMalaria ParasitaemiaMalariaNCT07548021Medicines for Malaria Venture80
招募中
1 期
A Study to Evaluate ALN-2232 in Participants With ObesityObesityNCT07463846Alnylam Pharmaceuticals156
招募中
1 期
A Study to Investigate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of AZD1043 in Healthy Adult Participants Living With Overweight and/or Obesity.Healthy ParticipantsObesityNCT07511205AstraZeneca104